Validation of a Food Frequency Questionnaire for the Assessment of Omega-3 Fatty Acid Intake

Validation of a Food Frequency Questionnaire for the Assessment of Omega-3

As essential nutrients omega 3 fatty acids contribute to normal growth and development. Inadequate intake is linked to the development of chronic diseases such as coronary heart disease, high blood pressure, cancer, arthritis, psychological illnesses and allergies. Therefore, it is important to be able to reliably detect the intake of these fatty acids. Due to eating habits varying in different countries the questionnaire documenting dietary habits needs to be adapted to the situation in question. Based on a US version the investigators developed a questionnaire suitable for Switzerland and now wish to validate it by measuring the fatty acid composition of red blood cells, which will provide information on the intake of the various fatty acids.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Other: no intervention

• Study Type: Observational
• Enrollment (Actual): 152

Contacts and Locations

Study Locations

• Switzerland
  • Zürich, Switzerland, 8092
    • ETH Zurich

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Healthy adults

Description

Inclusion Criteria:

• healthy males and females aged 18 to 60

Exclusion Criteria:

• known disorders of the gastrointestinal tract which can lead to malabsorption
• intake of medication which could affect the absorption of any nutrients
• Pregnant or breast-feeding women

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Fatty acid composition of red blood cells due to dietary habits	Fatty acid composition of red blood cells due to dietary habits	1 day ( first visit)

Collaborators and Investigators

• Sponsor: Isabelle Herter-Aeberli
• Collaborators: University Children's Hospital, Zurich

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 15, 2018
• Primary Completion (ACTUAL): July 25, 2018
• Study Completion (ACTUAL): July 25, 2018

Study Registration Dates

• First Submitted: January 18, 2018
• First Submitted That Met QC Criteria: January 23, 2018
• First Posted (ACTUAL): January 24, 2018

Study Record Updates

• Last Update Posted (ACTUAL): July 26, 2018
• Last Update Submitted That Met QC Criteria: July 25, 2018
• Last Verified: July 1, 2018

More Information

Terms related to this study

• Other Study ID Numbers: N3FFQ

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No